Lantern Pharma Inc.
LTRN · NASDAQ
Bulios Fair Price
$2.28
33.3% upside
Current Price
$1.71
According to Bulios Fair Price, LTRN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Lantern Pharma Inc. is a biotechnology company focused on developing personalized therapeutic approaches for cancer patients. The company utilizes advanced bioinformatics and artificial intelligence to identify genetic and molecular characteristics of cancer tumors, enabling better targeting of therapeutic strategies for individual patients. Lantern Pharma focuses on discovering and developing new drugs and combination therapies that could be effective in patients with various types of cancer, including those who have not been successfully treated by standard methods. The goal of Lantern Pharma is to bring innovative treatment approaches and improve treatment outcomes for cancer patients.
Sector
Healthcare
Industry
Biotechnology
CEO
Panna Sharma
Employees
16
Headquarters
Dallas
Upcoming events
Earnings
Upcoming earnings report